Publications by authors named "Francis Burrows"

Claim this Profile
A
Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancers.
Dinesh Babu Manikandan, Sankar Jagadeeshan, Sooraj Mathukkada, Raghda Abu Shareb, Manu Prasad, Francis Burrows

Neoplasia· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo CRISPR screens identify a dual function of MEN1 in regulating tumor-microenvironment interactions.
Peiran Su, Yin Liu, Tianyi Chen, Yibo Xue, Yong Zeng, Francis Burrows

Nat Genet· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies.
Sarah Figarol, Célia Delahaye, Rémi Gence, Aurélia Doussine, Juan Pablo Cerapio, Francis Burrows

Nat Commun· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma.
Sankar Jagadeeshan, Kushal Suryamohan, Nara Shin, Sooraj Mathukkada, Alexandra Boyko, Francis Burrows

Oral Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with rearrangement or mutation to venetoclax.
Johanna Rausch, Margarita M Dzama, Nadezda Dolgikh, Hanna L Stiller, Stephan R Bohl, Francis Burrows

Haematologica· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity.
Alison E Smith, Stacia Chan, Zhiyong Wang, Asako McCloskey, Quinn Reilly, Francis Burrows

Cancer Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutated HRAS Activates YAP1-AXL Signaling to Drive Metastasis of Head and Neck Cancer.
Sankar Jagadeeshan, Manu Prasad, Mai Badarni, Talal Ben-Lulu, Vijayasteltar Belsamma Liju, Francis Burrows

Cancer Res· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1.
Warren Fiskus, Naval Daver, Steffen Boettcher, Christopher P Mill, Koji Sasaki, Francis Burrows

Leukemia· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CXCL12 in Pancreatic Cancer: Its Function and Potential as a Therapeutic Drug Target.
Shivani Malik, Jill M Westcott, Rolf A Brekken, Francis J Burrows

Cancers (Basel)· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential of Farnesyl Transferase Inhibitors in Combination Regimens in Squamous Cell Carcinomas.
Linda Kessler, Shivani Malik, Mollie Leoni, Francis Burrows

Cancers (Basel)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action.
Rong Chen, Jennifer Tsai, Philip A Thompson, Yuling Chen, Ping Xiong, Francis Burrows

Blood Cancer J· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tipifarnib as a Precision Therapy for -Mutant Head and Neck Squamous Cell Carcinomas.
Mara Gilardi, Zhiyong Wang, Marco Proietto, Anastasia Chillà, Juan Luis Calleja-Valera, Francis Burrows

Mol Cancer Ther· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma.
Ruth Alonso-Alonso, Rufino Mondéjar, Nerea Martínez, Nuria García-Diaz, Cristina Pérez, Francis Burrows

Sci Rep· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia.
Szymon Klossowski, Hongzhi Miao, Katarzyna Kempinska, Tao Wu, Trupta Purohit, Francis Burrows

J Clin Invest· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer.
Yuqing Zhang, Amanda Kirane, Huocong Huang, Noah B Sorrelle, Francis J Burrows

Mol Cancer Res· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells.
Monica Pallis, Francis Burrows, Jeremy Ryan, Martin Grundy, Claire Seedhouse

Oncotarget· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
Nancy Levin, Andrew Spencer, Simon J Harrison, Dharminder Chauhan, Francis J Burrows

Br J Haematol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma.
Katelyn G Ponder, Shannon M Matulis, Sadae Hitosugi, Vikas A Gupta, Cathy Sharp, Francis Burrows

Cancer Biol Ther· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
Kaijun Di, G Kenneth Lloyd, Vivek Abraham, Ann MacLaren, Francis J Burrows

Neuro Oncol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mycobacterial Protein Tyrosine Phosphatases A and B Inhibitors Augment the Bactericidal Activity of the Standard Anti-tuberculosis Regimen.
Noton K Dutta, Rongjun He, Michael L Pinn, Yantao He, Francis Burrows

ACS Infect Dis· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic potential of ERK5 targeting in triple negative breast cancer.
María Jesús Ortiz-Ruiz, Stela Álvarez-Fernández, Tracy Parrott, Sara Zaknoen, Francis J Burrows

Oncotarget· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Barbara J Gitlitz, Eric Bernstein, Edgardo S Santos, Greg A Otterson, Ginger Milne, Francis Burrows

J Thorac Oncol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.
Monica Pallis, Francis Burrows, Abigail Whittall, Nicholas Boddy, Claire Seedhouse

BMC Pharmacol Toxicol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent antimyeloma activity of a novel ERK5/CDK inhibitor.
Stela Álvarez-Fernández, María Jesús Ortiz-Ruiz, Tracy Parrott, Sara Zaknoen, Enrique M Ocio, Francis J Burrows

Clin Cancer Res· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EC144 is a potent inhibitor of the heat shock protein 90.
Jiandong Shi, Ryan Van de Water, Kevin Hong, Ryan B Lamer, Kenneth W Weichert, Francis J Burrows

J Med Chem· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis